In this podcast with Dr. Eddy Lang and world expert troponin researcher Dr. Andrew McRae, we answer the not-so-simple questions…
EM Cases: Low Risk Chest Pain and High Sensitivity Troponin – A Paradigm Shift Read More »
CCTA has become a popular modality in the ED setting to assess anatomic atherosclerotic disease in patients presenting with chest pain. Advocates of CCTA feel that CCTA has a greater accuracy in identifying obstructive coronary artery disease and identification of high-risk disease compared to standard physiologic testing. However, many published trials on CCTA were not adequately powered to evaluate patient oriented end points.
Coronary CTA has risen to the forefront of chest pain evaluation, providing an anatomical evaluation of coronary artery vasculature. When negative, it improves negative predictive value of ACS. Additionally, CCTA allows for a better means to diagnose CAD when compared to history, physical exam, ECG, and biomarkers. But, is CCTA useful to further risk stratify low-risk patients? Who might benefit from CCTA and what are the risks?
Chest Pain Controversies: Coronary CTA Use (Part 2) Read More »